Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372702 | PMC |
| http://dx.doi.org/10.1038/s41386-018-0292-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
National Addiction Workshop: A Virtual Adaptation to Support Competency Development in Opioid Use Disorder Management.
Subst Use Addctn J
January 2025
Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Background: Accessible, manualized, skill-based training ready for wide dissemination is needed to prepare healthcare staff to meet the needs of people impacted by the opioid epidemic.
Methods: A 2-day workshop and simulation training was designed by an interprofessional substance use disorder (SUD) specialty care team, adapted to a virtual platform, manualized, and offered to healthcare staff and trainees from a large healthcare system. The workshop was offered 6 times over the course of 10 months with a total of 177 participants from across the United States enrolled in the training.
Retention and critical outcomes among new methadone maintenance patients following extended take-home reforms: a retrospective observational cohort study.
Lancet Reg Health Am
December 2023
Columbia University Department of Psychiatry, New York, USA.
Background: Approximately 1800 opioid treatment programs (OTPs) in the US dispense methadone to upwards of 400,000 patients with opioid use disorder (OUD) annually, operating under longstanding highly restrictive guidelines. OTPs were granted novel flexibilities beginning March 15, 2020, allowing for reduced visit frequency and extended take-home doses to minimize COVID exposure with great variation across states and sites. We sought to use electronic health records to compare retention in treatment, opioid use, and adverse events among patients newly entering methadone maintenance in the post-reform period in comparison with year-ago, unexposed, controls.
View Article and Find Full Text PDFSecondary Analysis of Agreement Between Negative Timeline Follow Back Report and Negative Urine Toxicology in a Large Trial of Individuals with Opioid Use Disorder.
J Addict Med
November 2023
From the New York State Psychiatric Institute, New York City, NY (MS, T-HC, JS, ANCC, MG, EVN); Department of Psychiatry, Columbia University Medical Center, New York, NY (MS, ANCC, MG, EVN); Department of Biostatistics, Mailman School of Public Health, Columbia University, New York City, NY (MP); Department of Psychiatry, New York University School of Medicine, New York City, NY (JR); and Department of Population Health, New York University, New York City, NY (PN, JDL).
Objectives: Timeline follow-back (TLFB) is a self-report measure commonly used as a method of assessing historical drug use in both clinical and research settings. Our study considered rates of agreement between TLFB and an objective biological assay of opioid use.
Methods: We calculated the rates of agreement between negative report of opioid use for the most recent 8 days on TLFB and urine toxicology (UTOX) results in a large multisite opioid use disorder treatment trial.
Clinical and psychosocial outcomes by sex among individuals prescribed buprenorphine-naloxone (BUP-NX) or extended-release naltrexone (XR-NTX) for opioid use disorder.
Am J Addict
November 2023
New York State Psychiatric Institute, Department of Psychiatry, Division on Substance Use Disorders, Columbia University Irving Medical Center, New York, New York, USA.
Background And Objectives: Limited research has explored sex differences in opioid use disorder medication (MOUD) treatment outcomes. The purpose of this study was to examine MOUD initiation onto buprenorphine-naloxone (BUP-NX) versus extended-release naltrexone (XR-NTX) by sex, and sex differences in clinical and psychosocial outcomes.
Methods: Using data from a 24-week open-label comparative effectiveness trial of BUP-NX or XR-NTX, this study examined MOUD initiation (i.
Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): A stepped wedge hybrid type 1 effectiveness-implementation study.
Contemp Clin Trials
May 2023
New York State Psychiatric Institute and Columbia University Irving Medical Center, New York, NY, United States of America. Electronic address:
Background: Extended-release injectable naltrexone (XR-NTX) is an effective treatment for opioid use disorder (OUD), but initiation remains a barrier to implementation. Standard practice requires a 10- to 15-day inpatient admission prior to XR-NTX initiation and involves a methadone or buprenorphine taper followed by a 7- to 10-day washout, as recommended in the Prescribing Information for XR-NTX. A 5- to 7-day rapid induction approach was developed that utilizes low-dose oral naltrexone and non-opioid medications.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!